Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveThe base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) BioPharma Dive The base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly to buy trio of vaccine developers in $3.8bn outlayNext: FDA delays verdict on AZ breast cancer drug Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
